IL148071A0 - Method for treatment of symptoms of central nervous system disorders - Google Patents

Method for treatment of symptoms of central nervous system disorders

Info

Publication number
IL148071A0
IL148071A0 IL14807100A IL14807100A IL148071A0 IL 148071 A0 IL148071 A0 IL 148071A0 IL 14807100 A IL14807100 A IL 14807100A IL 14807100 A IL14807100 A IL 14807100A IL 148071 A0 IL148071 A0 IL 148071A0
Authority
IL
Israel
Prior art keywords
symptoms
treatment
nervous system
central nervous
system disorders
Prior art date
Application number
IL14807100A
Other languages
English (en)
Original Assignee
Milkhaus Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milkhaus Lab Inc filed Critical Milkhaus Lab Inc
Publication of IL148071A0 publication Critical patent/IL148071A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL14807100A 1999-09-14 2000-05-05 Method for treatment of symptoms of central nervous system disorders IL148071A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15383899P 1999-09-14 1999-09-14
US09/514,993 US6187309B1 (en) 1999-09-14 2000-02-29 Method for treatment of symptoms of central nervous system disorders
PCT/US2000/012326 WO2001019398A1 (en) 1999-09-14 2000-05-05 Method for treatment of symptoms of central nervous system disorders

Publications (1)

Publication Number Publication Date
IL148071A0 true IL148071A0 (en) 2002-09-12

Family

ID=26850911

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14807100A IL148071A0 (en) 1999-09-14 2000-05-05 Method for treatment of symptoms of central nervous system disorders
IL148071A IL148071A (en) 1999-09-14 2002-02-06 Use of anti-rubeola antibodies to make a pharmaceutical composition for treating the symptoms of autism

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148071A IL148071A (en) 1999-09-14 2002-02-06 Use of anti-rubeola antibodies to make a pharmaceutical composition for treating the symptoms of autism

Country Status (9)

Country Link
US (1) US6187309B1 (ja)
EP (1) EP1212088B1 (ja)
JP (1) JP3762891B2 (ja)
AT (1) ATE324908T1 (ja)
AU (1) AU781889B2 (ja)
CA (1) CA2391808C (ja)
DE (1) DE60027732T2 (ja)
IL (2) IL148071A0 (ja)
WO (1) WO2001019398A1 (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6436401B1 (en) * 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6713058B2 (en) * 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
WO2003028668A2 (en) * 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
US20090011048A1 (en) * 2002-04-16 2009-01-08 Coleman Henry D Dietary Supplement For Promoting Removal Of Heavy Metals From The Body
US20040107413A1 (en) * 2002-11-22 2004-06-03 Bixler John D. Autism treatment system and method
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20080058282A1 (en) * 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
AU2008203703C1 (en) * 2007-01-05 2014-04-03 University Of Zurich Method of providing disease-specific binding molecules and targets
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) * 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
DK3064217T3 (en) 2009-01-06 2018-05-28 Galenagen Llc COMPOSITIONS COMPREHENSIVE PROTEASE, AMYLASE AND LIPASE FOR USE IN TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
ES2726978T3 (es) 2011-04-21 2019-10-11 Curemark Llc Compuestos para el tratamiento de trastornos neuropsiquiátricos
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JOP20200041A1 (ar) 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3408M (fr) * 1964-03-25 1965-07-05 Michel Plissier Immunoglobulines d'origine animale, antivirus de la rougeole, seules ou associées a d'autres immunoglobulines ou médicaments.
JPS56113713A (en) * 1980-02-14 1981-09-07 Chemo Sero Therapeut Res Inst Preparation of immunoglobulin with high content of monomer
US4521405A (en) * 1982-05-17 1985-06-04 John McMichael Methods and materials for treatment of disease states involving immunological factors
JPS59157017A (ja) * 1983-02-25 1984-09-06 Green Cross Corp:The 静脈投与用γ−グロブリン製剤

Also Published As

Publication number Publication date
DE60027732D1 (de) 2006-06-08
EP1212088A1 (en) 2002-06-12
CA2391808C (en) 2008-10-28
AU4822800A (en) 2001-04-17
IL148071A (en) 2008-07-08
JP3762891B2 (ja) 2006-04-05
CA2391808A1 (en) 2001-03-22
AU781889B2 (en) 2005-06-23
US6187309B1 (en) 2001-02-13
ATE324908T1 (de) 2006-06-15
DE60027732T2 (de) 2006-09-14
JP2003509382A (ja) 2003-03-11
EP1212088B1 (en) 2006-05-03
WO2001019398A1 (en) 2001-03-22
EP1212088A4 (en) 2004-08-18

Similar Documents

Publication Publication Date Title
IL148071A0 (en) Method for treatment of symptoms of central nervous system disorders
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
MY124786A (en) Bis-arylsulfones
ZA9711279B (en) Method for treating and preventing neurological disorders and promoting wound healing.
EP1793671A4 (en) USE OF MEMANTINE (NAMENDA) FOR THE TREATMENT OF AUTISM, FORCED BEHAVIOR AND IMPULSIVITY
EP1839657A3 (en) A method for treating vascular headaches
EP1434801A4 (en) TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
MXPA03010911A (es) Anticuerpos contra ngf para el tratamiento de varios desordenes.
AP2002002620A0 (en) Substituted arylpyrazines
EP1085862A4 (en) METHODS OF TREATING AUTOIMMUNE DISEASES
PL328858A1 (en) Immunogenous peptides
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
EE200300559A (et) Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks
GB9212308D0 (en) Therapeutic compositions
DE69635213D1 (de) Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
IL114296A0 (en) Method for treating patients suffering from drug dependencies which lead to plasma melatonin deficiencies
EP0769957A4 (en) METHOD FOR TREATING ENGINE DEFICIT
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
IL128028A0 (en) Treatment of psychotic disorders
EP1056458A4 (en) METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
WO2004016604A3 (en) Azabicyclic compounds are central nervous system active agents
EP1143942A3 (en) Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases
MXPA04000344A (es) Combinacion de principios activos para la terapia medicinal de la dependencia a la nicotina.

Legal Events

Date Code Title Description
KB Patent renewed